R Squared Ltd Has $899,000 Position in Colgate-Palmolive Company $CL

R Squared Ltd lifted its position in shares of Colgate-Palmolive Company (NYSE:CL) by 196.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 11,240 shares of the company’s stock after purchasing an additional 7,445 shares during the period. R Squared Ltd’s holdings in Colgate-Palmolive were worth $899,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Westside Investment Management Inc. increased its position in Colgate-Palmolive by 85.5% during the second quarter. Westside Investment Management Inc. now owns 282 shares of the company’s stock worth $26,000 after buying an additional 130 shares during the last quarter. Copia Wealth Management acquired a new position in shares of Colgate-Palmolive during the 3rd quarter worth approximately $29,000. Vermillion & White Wealth Management Group LLC raised its stake in Colgate-Palmolive by 86.1% in the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 335 shares of the company’s stock valued at $30,000 after acquiring an additional 155 shares during the period. Cloud Capital Management LLC acquired a new stake in Colgate-Palmolive during the 3rd quarter valued at $30,000. Finally, MTM Investment Management LLC bought a new position in Colgate-Palmolive during the second quarter worth $39,000. 80.41% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently issued reports on CL. Weiss Ratings restated a “hold (c)” rating on shares of Colgate-Palmolive in a research note on Wednesday, January 21st. The Goldman Sachs Group restated a “buy” rating and set a $100.00 price objective on shares of Colgate-Palmolive in a report on Friday, February 20th. Morgan Stanley increased their target price on Colgate-Palmolive from $87.00 to $100.00 and gave the stock an “overweight” rating in a research note on Monday, February 2nd. Jefferies Financial Group boosted their price target on Colgate-Palmolive from $85.00 to $91.00 and gave the company a “hold” rating in a research note on Monday, February 2nd. Finally, Wells Fargo & Company increased their price objective on Colgate-Palmolive from $86.00 to $94.00 and gave the stock an “equal weight” rating in a research report on Sunday, February 1st. Eleven equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Colgate-Palmolive currently has a consensus rating of “Moderate Buy” and a consensus price target of $94.75.

Insider Activity at Colgate-Palmolive

In other Colgate-Palmolive news, COO Panagiotis Tsourapas sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 12th. The shares were sold at an average price of $97.81, for a total value of $1,467,150.00. Following the sale, the chief operating officer owned 10,415 shares in the company, valued at $1,018,691.15. This trade represents a 59.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Sally Massey sold 15,851 shares of the business’s stock in a transaction on Thursday, February 5th. The stock was sold at an average price of $95.03, for a total transaction of $1,506,320.53. Following the sale, the insider directly owned 13,751 shares in the company, valued at approximately $1,306,757.53. The trade was a 53.55% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 184,683 shares of company stock valued at $17,486,693. 0.34% of the stock is currently owned by company insiders.

Colgate-Palmolive Stock Up 0.9%

NYSE CL opened at $97.50 on Friday. The business has a fifty day moving average price of $87.08 and a two-hundred day moving average price of $82.63. The stock has a market capitalization of $78.59 billion, a PE ratio of 37.21, a PEG ratio of 4.36 and a beta of 0.29. Colgate-Palmolive Company has a fifty-two week low of $74.54 and a fifty-two week high of $100.18. The company has a debt-to-equity ratio of 18.82, a current ratio of 0.83 and a quick ratio of 0.27.

Colgate-Palmolive (NYSE:CL) last announced its quarterly earnings data on Friday, January 30th. The company reported $0.95 earnings per share for the quarter, topping the consensus estimate of $0.91 by $0.04. The business had revenue of $5.23 billion during the quarter, compared to the consensus estimate of $5.13 billion. Colgate-Palmolive had a return on equity of 353.72% and a net margin of 10.45%.Colgate-Palmolive’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the prior year, the company earned $0.91 EPS. Equities analysts expect that Colgate-Palmolive Company will post 3.75 earnings per share for the current fiscal year.

Colgate-Palmolive Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, February 13th. Stockholders of record on Wednesday, January 21st were issued a $0.52 dividend. The ex-dividend date of this dividend was Wednesday, January 21st. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.1%. Colgate-Palmolive’s dividend payout ratio is 79.39%.

Colgate-Palmolive Company Profile

Colgate-Palmolive Company is a global consumer products company with a long history in household and personal care categories. The business traces its roots to the early 19th century and has evolved into a multinational manufacturer and marketer of everyday consumer goods focused on health, hygiene and home care.

The company’s core activities center on oral care, personal care, home care and pet nutrition. Its product portfolio includes toothpaste, toothbrushes and mouthwash in oral care; soaps, body washes and deodorants in personal care; dishwashing liquids, surface cleaners and other household products in home care; and scientifically formulated pet foods under its pet nutrition business.